ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,550Medicare Part D Prescriptions Filled, Including Refills

Rank: 179 out of 680

$602K Total Retail Price of All Prescriptions

Rank: 214 out of 680

361 Patients Receiving at Least One Drug in Part D
72%Patients 65 Years and Older
60% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

5% of this provider’s 361 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

3% of this provider’s 8,709 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$52 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
TRAMADOL HCL 480 364 1 18
METFORMIN HCL 385 256 2 8
AMLODIPINE BESYLATE 340 277 3 1
PRAVASTATIN SODIUM 319 245 4 10
LOSARTAN-HYDROCHLOROTHIAZIDE 298 247 5 51
OMEPRAZOLE 297 201 6 7
FUROSEMIDE 274 190 7 6
SPIRONOLACTONE 264 214 8 82
LISINOPRIL 261 190 9 5
LOSARTAN POTASSIUM 230 203 10 21
SIMVASTATIN 225 195 11 3
POTASSIUM CHLORIDE 225 171 11 14
METOPROLOL TARTRATE 219 170 13 12
LISINOPRIL-HYDROCHLOROTHIAZIDE 205 168 14 37
GLIMEPIRIDE 203 185 15 29
FAMOTIDINE 201 164 16 89
GABAPENTIN 199 142 17 15
CARVEDILOL 172 119 18 23
WARFARIN SODIUM 171 110 19 20
LEVOTHYROXINE SODIUM 169 127 20 2
FLUTICASONE PROPIONATE 167 123 21 41
CLOPIDOGREL 166 130 22 26
SERTRALINE HCL 152 127 23 28
METOPROLOL SUCCINATE 147 126 24 13
CLONIDINE HCL 145 112 25 36
DONEPEZIL HCL 138 130 26 27
LOVASTATIN 131 104 27 44
ATORVASTATIN CALCIUM 127 93 28 11
NEXIUM 126 62 29 16
ATENOLOL 125 112 30 19
PEN NEEDLE 111 70 31 122
ZOLPIDEM TARTRATE 102 78 32 17
SINGULAIR 98 67 33 91
FLUOXETINE HCL 96 73 34 74
JANUVIA 92 78 35 60
DIOVAN HCT 88 69 36 55
COLCRYS 87 72 37 166
NAMENDA 84 84 38 35
LANTUS 82 49 39 49
AMITRIPTYLINE HCL 82 65 R 39 47
PLAVIX 81 64 41 39
ALLOPURINOL 78 59 42 33
LANTUS SOLOSTAR 77 51 43 84
NIFEDIPINE ER 75 53 44 75
PANTOPRAZOLE SODIUM 72 68 45 30
CYMBALTA 68 59 46 46
DIGOXIN 68 61 46 58
RANITIDINE HCL 67 66 48 56
HYDROCODONE-ACETAMINOPHEN 65 53 S3 49 4
DIOVAN 63 47 50 31
CYCLOBENZAPRINE HCL 62 37 R 51 81
MONTELUKAST SODIUM 61 34 52 157
HYDROCHLOROTHIAZIDE 60 53 53 9
ISOSORBIDE MONONITRATE ER 57 41 54 59
SPIRONOLACTONE-HCTZ 51 45 55 259
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 9, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.